Agilent secures expanded CE Mark for cancer assay

2020 04 14 17 10 6379 Test Tubes Rd Lab 400

Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy agent -- to be used for esophageal cancer.

The test may now be used to identify esophageal cancer patients eligible for treatment with Keytruda, a monoclonal antibody developed by Merck that boosts the body's ability to fight cancer cells.

Page 1 of 1